EUVIMEDEUVIMED entdecken
Crossref

Ranibizumab versus bevacizumab in choroidal neovascular membrane: Is it worth it?

Abeer Khattab

Journal of the Egyptian Ophthalmological Society · 2013

DOI: 10.4103/2090-0686.127356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Egyptian Ophthalmological Society, 2013. Verfasst von Abeer Khattab.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeThe aim of this study was to compare the short-term outcomes of administration of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of neovascular age-related macular degeneration (AMD).DesignThis study is a clinical interventional randomized comparative study.Patients and methodsThis randomized clinical trial was performed on 24 eyes of 24 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD. The eyes were randomly assigned to receive 0.5 mg IVR (group 1; 12 eyes) or 1.25 mg IVB (group 2; (12 eyes). Best-corrected visual acuity (BCVA) was assessed, optical coherence tomography was carried out at baseline and repeated at all postoperative follow-up intervals (1 week and 1, 3, and 6 months), and fluorescein angiography was performed at baseline and repeated 1 month after treatment.ResultsIn group 1, the mean age was 62.42 ± 6.75 years (range 51-70 years) and seven of the patients were male (58.33%). In group 2, the mean age was 62.083 ± 7.96 years (range 50-75 years) and four of the patients were male (33.33%). At the sixth month postoperatively, BCVA logMAR significantly improved from 1.01 ± 0.26 (range 1.5-0.7) to 0.82 ± 0.18 (range 1.2-0.5; P = 0.001) in group 1 and from 0.98 ± 0.279 (range 1.4-0.5) to 0.81 ± 0124 (range 1.0-0.7; P = 0.004) in group 2. At 6 months postoperatively, the mean ± SD central macular thickness reduced from 363.33 ± 27.16 μm at baseline (range 319-405 μm) to 291.67 ± 25.79 μm (range 243-335 μm) in group 1 (P = 0.00), whereas in group 2, the mean ± SD central macular thickness moderately reduced from 362.5 ± 20.26 μm at baseline (range 339-400 μm) to 294.17 ± 29.62 μm (range 257-350 μm) at 6 months postoperatively (P = 0.00). There were no significant systemic or ophthalmological adverse effects in either group.ConclusionBoth ranibizumab and bevacizumab are equally safe and effective treatment options as intravitreal injections in the treatment of CNVM due to AMD.

Zitieren

APA

Khattab, A. (2013). Ranibizumab versus bevacizumab in choroidal neovascular membrane: Is it worth it?. Journal of the Egyptian Ophthalmological Society. https://doi.org/10.4103/2090-0686.127356

Vancouver

Khattab A. Ranibizumab versus bevacizumab in choroidal neovascular membrane: Is it worth it?. Journal of the Egyptian Ophthalmological Society. 2013. doi:10.4103/2090-0686.127356

BibTeX
@article{Khattab2013,
  author = {Khattab, Abeer},
  title = {Ranibizumab versus bevacizumab in choroidal neovascular membrane: Is it worth it?},
  journal = {Journal of the Egyptian Ophthalmological Society},
  year = {2013},
  doi = {10.4103/2090-0686.127356}
}
Kostenlos starten →